Clinical Trial Search

Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) — 8.8; -29.7; -44.0; -47.2 Percent…

Primary: Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans) — 67 percentage of positive scans — p=0.317

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Related to Study Drug — 100; 96.5; 36.0; 54.1 percentage of…

Primary: Change in Insomnia Severity — -6.60; -3.46 score on a scale — p=0.0002

Primary: Sun Protection Behavior Index — 3.54; 3.37 scores on a scale

Primary: Self-reported Satisfaction With the Screening Process — 94; 97; 12; 15 Participants

Primary: Efficacy: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or Dialysis — 27; 25 participants — p=>0.05

Primary: Frequency of Tumor Response at 9 Months After Last Treatment — 0; 1; 19; 15 Participants

Primary: Visual Index Ichthyosis Severity (VIIS) Scaling Score as Assessed by the Investigator in ADX-102 Treated Patients — -0.7 units on a scale

Primary: Change of the WOMAC Pain Subscale at Day 28 From Baseline — -14.33; -12.47; -13.24 units on a scale

Primary: Percentage of Participants With Covid-19 Related Hospitalization or Death From Any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population — 0.752; 6.888…

Primary: Percentage of Patients Responders and Non-responders at Week 24 — 30.4; 55.6; 69.6; 44.4 Percentage of participants

Primary: Maximum Tolerated Dose — 2.24 mg/m^2

Primary: Time to Hemostasis — 19; 120; 44; 45 minutes

Primary: Number of Participants With Any Treatment Emergent Adverse Event (TEAE) — 8; 7; 1; 4 Participants